Kansanterveyslaitos KTL

Viitteet 1-3 / 3

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

Villa LL; Costa RL; Petta CA; Andrade RP; Paavonen J; Iversen OE; Olsson SE; Hoye J; Steinwall M; Riis-Johannessen G; Andersson-Ellstrom A; Elfgren K; Lupinacci L; Railkar R; Taddeo FJ; Bryan J; Esser MT; Sings HL; Saah AJ; Barr E
Br J Cancer : 11 (2006)
Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18

Villa LL; Ault KA; Giuliano AR; Costa RLR; Petta CA; Andrade RP; Brown DR; Ferency A; Harper DM; Koutsky LA; Kurman RJ; Lehtinen M; Malm C; Olsson S-E; Ronnett BM; Skjeldestad FE; Steinwall M; Stoler MH; Wheeler CM; Taddeo FJ; Yu J; Lupinacci L; Railkar R; Marchese R; Esser MT; Bryan J; Jansen KU; Sings HL; Tamms GM; Saah AJ; Barr E
Vaccine : 27-28 (2006)
Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine

Olsson S-E; Villa LL; Costa RLR; Petta CA; Andrade RP; Malm C; Iversen O-E; Hoye J; Steinwall M; Riis-Johannessen G; Andersson-Ellstrom A; Elfgren K; Krogh G van; Lehtinen M; Paavonen J; Tamms GM; Giacoletti K; Lupinacci L; Esser MT; Vuocolo SC; Saah AJ; Barr E
Vaccine : 26 (2007)

"Saah AJ" - Selaus tekijän mukaan Kansanterveyslaitos KTL